Lupin, one of India’s major pharmaceuticals companies, has announced that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and sell Levofloxacin tablet.

The approval has been granted for Levofloxacin tablet in three potencies, 250 mg, 500 mg and 750 mg.

Levofloxacin is a synthetic chemotherapeutic agent, which is recommended for the treatment of severe and life threatening bacterial infections.

Stock of Lupin ended the day in green at Rs 849, up 8.72% on Bombay Stock Exchange (BSE). The stock has also hit 52-week high on Monday’s trading session.